Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease

Executive Summary

Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.

You may also be interested in...



Novartis Looks To Lead CAR-T Expansion Into Autoimmune Disease

Novartis pioneered CAR-Ts for leukemia and lymphoma, and inspired by pioneering physician Georg Schett, it also hopes to be first in the race to revolutionize autoimmune disease treatment with the therapies, and has unveiled the first clinical data for its candidate.

Sana Curbs Cell Therapy Ambitions Again, Including Retreat From In Vivo CAR-T

Launched with an ambitious R&D vision for cell therapies two years ago, Sana is now having to narrow its focus while it awaits the first of its Phase I readouts.

Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence

The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel